Target Name: DCLRE1B
NCBI ID: G64858
Review Report on DCLRE1B Target / Biomarker Content of Review Report on DCLRE1B Target / Biomarker
DCLRE1B
Other Name(s): Beta-lactamase DCLRE1B | PSO2 homolog | DCLRE1B variant 1 | 5' exonuclease Apollo | hSNM1B | SNM1B | APOLLO | DCR1B_HUMAN | DNA cross-link repair 1B, transcript variant 1 | DNA cross-link repair 1B (P

DCLRE1B: A Potential Drug Target for Beta-Lactam Antibiotics

DCLRE1B (Beta-lactamase DCLRE1B) is a gene that encodes a protein known as beta-lactamase DCLRE1B. Beta-lactamase is a type of enzyme that is involved in the production of beta-lactam antibiotics, which are commonly used in the treatment of bacterial infections. DCLRE1B is a gene that has been identified as a potential drug target or biomarker for the treatment of various diseases, including bacterial infections, cancer, and neurodegenerative diseases.

The beta-lactamase enzyme is a key player in the production of beta-lactam antibiotics. These antibiotics are derived from the bacteria that cause infections, and they are often used to treat bacterial infections such as strep throat, pneumonia, and meningitis. Beta-lactam antibiotics work by inhibiting the activity of the beta-lactamase enzyme, which is responsible for breaking down the beta-lactam ring found in the center of many antibiotics. This ring is the source of the antibiotic's activity, and by inhibiting its activity, the beta-lactam antibiotic can effectively kill bacteria.

DCLRE1B is a gene that has been shown to be involved in the production of beta-lactam antibiotics. In fact, studies have shown that DCLRE1B is highly expressed in many bacteria, including those that are commonly used as therapeutic agents. For example, DCLRE1B is highly expressed in Staphylococcus aureus, a bacteria that is commonly used as a therapeutic agent for a variety of conditions, including strep throat, pneumonia, and surgical wound infections.

In addition to its role in the production of beta-lactam antibiotics, DCLRE1B is also thought to have other functions. For example, it has been shown to be involved in the regulation of bacterial cell wall biosynthesis, which is the process by which bacteria produce the cell wall that surrounds them. This may be important for the development of antibiotic resistance, as the ability of bacteria to produce beta-lactam antibiotics can be influenced by changes in the cell wall biosynthesis pathway.

DCLRE1B is also thought to be involved in the regulation of bacterial replication and transcription. This is important for the growth and spread of many bacteria, including those that are causative of disease. For example, DCLRE1B has been shown to be involved in the regulation of bacterial replication in response to various stimuli, including the presence of antibiotics.

In addition to its functions in cell wall biosynthesis and replication, DCLRE1B is also thought to be involved in the regulation of bacterial stress responses. This is important for the survival of many bacteria, including those that are causing disease. For example, studies have shown that DCLRE1B is involved in the regulation of bacterial stress responses in response to various stressors, including the absence of oxygen and the presence of toxins.

DCLRE1B is also a potential biomarker for a variety of diseases, including cancer and neurodegenerative diseases. For example, studies have shown that DCLRE1B is highly expressed in many cancer cells, and that it is involved in the production of various cancer-associated biomarkers. This suggests that DCLRE1B may be a useful biomarker for the diagnosis and treatment of cancer.

In addition to its potential as a drug target or biomarker, DCLRE1B is also of interest from a fundamental biological perspective. The beta-lactamase enzyme is a key player in the production of many antibiotics that are used to treat bacterial infections. This suggests that the activity of this enzyme may be a useful target for the development of new antibiotics. For example, studies have shown that the synthesis of beta-lactam antibiotics is often limited by the availability of certain amino acids,

Protein Name: DNA Cross-link Repair 1B

Functions: 5'-3' exonuclease that plays a central role in telomere maintenance and protection during S-phase. Participates in the protection of telomeres against non-homologous end-joining (NHEJ)-mediated repair, thereby ensuring that telomeres do not fuse. Plays a key role in telomeric loop (T loop) formation by being recruited by TERF2 at the leading end telomeres and by processing leading-end telomeres immediately after their replication via its exonuclease activity: generates 3' single-stranded overhang at the leading end telomeres avoiding blunt leading-end telomeres that are vulnerable to end-joining reactions and expose the telomere end in a manner that activates the DNA repair pathways. Together with TERF2, required to protect telomeres from replicative damage during replication by controlling the amount of DNA topoisomerase (TOP1, TOP2A and TOP2B) needed for telomere replication during fork passage and prevent aberrant telomere topology. Also involved in response to DNA damage: plays a role in response to DNA interstrand cross-links (ICLs) by facilitating double-strand break formation. In case of spindle stress, involved in prophase checkpoint. Possesses beta-lactamase activity, catalyzing the hydrolysis of penicillin G and nitrocefin (PubMed:31434986). Exhibits no activity towards other beta-lactam antibiotic classes including cephalosporins (cefotaxime) and carbapenems (imipenem) (PubMed:31434986)

The "DCLRE1B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DCLRE1B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

DCLRE1C | DCN | DCP1A | DCP1B | DCP2 | DCPS | DCST1 | DCST1-AS1 | DCST2 | DCSTAMP | DCT | DCTD | DCTN1 | DCTN1-AS1 | DCTN2 | DCTN3 | DCTN4 | DCTN5 | DCTN6 | DCTPP1 | DCUN1D1 | DCUN1D2 | DCUN1D3 | DCUN1D4 | DCUN1D5 | DCX | DCX (DDB1-CUL4-X-box) E3 protein ligase complex | DCX DET1-COP1 ubiquitin ligase complex | DCX(DCAF15) E3 protein ligase complex | DCXR | DDA1 | DDAH1 | DDAH2 | DDB1 | DDB2 | DDC | DDC-AS1 | DDD core complex | DDHD1 | DDHD2 | DDI1 | DDI2 | DDIAS | DDIT3 | DDIT4 | DDIT4L | DDN | DDO | DDOST | DDR1 | DDR2 | DDRGK1 | DDT | DDTL | DDX1 | DDX10 | DDX11 | DDX11-AS1 | DDX11L1 | DDX11L10 | DDX11L2 | DDX11L8 | DDX11L9 | DDX12P | DDX17 | DDX18 | DDX18P1 | DDX19A | DDX19A-DT | DDX19B | DDX20 | DDX21 | DDX23 | DDX24 | DDX25 | DDX27 | DDX28 | DDX31 | DDX39A | DDX39B | DDX39B-AS1 | DDX3P1 | DDX3X | DDX3Y | DDX4 | DDX41 | DDX42 | DDX43 | DDX46 | DDX47 | DDX49 | DDX5 | DDX50 | DDX50P1 | DDX51 | DDX52 | DDX53 | DDX54 | DDX55 | DDX56